These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 26176181

  • 1. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.
    Yang TH, Chen YK, Xue F, Han LZ, Shen CH, Zhou T, Luo Y, Zhang JJ, Xia Q.
    Int J Clin Pract Suppl; 2015 May; (183):53-62. PubMed ID: 26176181
    [Abstract] [Full Text] [Related]

  • 2. CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients.
    Xue F, Han L, Chen Y, Xi Z, Li Q, Xu N, Xia Y, Streicher K, Zhang J, Xia Q.
    Pediatr Transplant; 2014 Mar; 18(2):166-76. PubMed ID: 24438215
    [Abstract] [Full Text] [Related]

  • 3. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
    Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA.
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
    [Abstract] [Full Text] [Related]

  • 4. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients.
    Muraki Y, Usui M, Isaji S, Mizuno S, Nakatani K, Yamada T, Iwamoto T, Uemoto S, Nobori T, Okuda M.
    Ann Transplant; 2011 Sep; 16(4):55-62. PubMed ID: 22210422
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation.
    Chen YK, Han LZ, Xue F, Shen CH, Lu J, Yang TH, Zhang JJ, Xia Q.
    PLoS One; 2014 Sep; 9(10):e109464. PubMed ID: 25310192
    [Abstract] [Full Text] [Related]

  • 7. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
    Wei-lin W, Jing J, Shu-sen Z, Li-hua W, Ting-bo L, Song-feng Y, Sheng Y.
    Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
    [Abstract] [Full Text] [Related]

  • 8. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE, Goodman LK, Tett SE.
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [Abstract] [Full Text] [Related]

  • 9. Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.
    Liu J, Ouyang Y, Chen D, Yao B, Lin D, Li Z, Zang Y, Liu H, Fu X.
    Int Immunopharmacol; 2018 Apr; 57():18-24. PubMed ID: 29454235
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients.
    Gómez-Bravo MA, Salcedo M, Fondevila C, Suarez F, Castellote J, Rufian S, Pons JA, Alamo JM, Millán O, Brunet M.
    J Clin Pharmacol; 2013 Nov; 53(11):1146-54. PubMed ID: 23900887
    [Abstract] [Full Text] [Related]

  • 14. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, Narita S, Tsuchiya N, Habuchi T, Miura M.
    Transplantation; 2012 Nov 27; 94(10):1013-9. PubMed ID: 23073468
    [Abstract] [Full Text] [Related]

  • 15. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE, Goodman LK, Tett SE.
    Clin Pharmacokinet; 2010 Mar 27; 49(3):141-75. PubMed ID: 20170205
    [Abstract] [Full Text] [Related]

  • 16. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
    Glowacki F, Lionet A, Buob D, Labalette M, Allorge D, Provôt F, Hazzan M, Noël C, Broly F, Cauffiez C.
    Nephrol Dial Transplant; 2011 Sep 27; 26(9):3046-50. PubMed ID: 21677300
    [Abstract] [Full Text] [Related]

  • 17. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
    Chen Z, Cheng X, Zhang L, Tang L, Fang Y, Chen H, Zhang L, Shen A.
    Pharmacol Rep; 2021 Oct 27; 73(5):1418-1426. PubMed ID: 34089513
    [Abstract] [Full Text] [Related]

  • 18. Impact of donor CYP3A5 genotype on pharmacokinetics of tacrolimus in South African paediatric liver transplant patients.
    Wheeler C, Masimirembwa C, Mthembu B, Botha J, Scholefield J, Fabian J.
    S Afr Med J; 2024 Apr 24; 114(3b):e1367. PubMed ID: 39041443
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
    Uesugi M, Kikuchi M, Shinke H, Omura T, Yonezawa A, Matsubara K, Fujimoto Y, Okamoto S, Kaido T, Uemoto S, Masuda S.
    Pharmacogenet Genomics; 2014 Jul 24; 24(7):356-66. PubMed ID: 24911663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.